{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:00:31Z","timestamp":1790269231157,"version":"4.1.0"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["5R01DK134347-02"],"award-info":[{"award-number":["5R01DK134347-02"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["5TL1DK139567-2"],"award-info":[{"award-number":["5TL1DK139567-2"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s00467-026-07384-6","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T16:26:36Z","timestamp":1780676796000},"page":"3813-3826","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Update on APOL1 and chronic kidney diseases in children"],"prefix":"10.1007","volume":"41","author":[{"given":"Jennifer D.","family":"Varner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Titilayo O.","family":"Ilori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5641-6644","authenticated-orcid":false,"given":"Rasheed A.","family":"Gbadegesin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"7384_CR1","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"KDIGO","year":"2024","unstructured":"KDIGO (2024) Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 105:S117-s314","journal-title":"Kidney Int"},{"key":"7384_CR2","unstructured":"(2025) Global, regional, and national burden of chronic kidney disease in adults, 1990\u20132023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. Lancet 406:2461\u20132482"},{"key":"7384_CR3","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1093\/ndt\/gfae048","volume":"39","author":"R Duff","year":"2024","unstructured":"Duff R, Awofala O, Arshad MT, Lambourg E, Gallacher P, Dhaun N, Bell S (2024) Global health inequalities of chronic kidney disease: a meta-analysis. Nephrol Dial Transplant 39:1692\u20131709","journal-title":"Nephrol Dial Transplant"},{"key":"7384_CR4","volume-title":"Lancet","author":"Global, regional, and national burden of chronic kidney disease in adults, 1990\u20132023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study","year":"2023","unstructured":"Global, regional, and national burden of chronic kidney disease in adults, 1990\u20132023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study (2023) Lancet. England, London"},{"key":"7384_CR5","volume-title":"USRDS annual data report: epidemiology of kidney disease in the United States","author":"United States Renal Data System","year":"2024","unstructured":"United States Renal Data System (2024) USRDS annual data report: epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD"},{"key":"7384_CR6","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000867","author":"J Bragg-Gresham","year":"2025","unstructured":"Bragg-Gresham J, Xu F, Han Y, Licon AL, Kiryakos J, Heung M, Morgenstern H, Weitzel W, Veinot T, Gillespie B, Modi ZJ, Herman W, Koehlmoos TP, Nee R, Oliver JD, Han S, Pavkov ME, Saran R (2025) Epidemiology of kidney disease in the United States: highlights from the Centers for Disease Control and Prevention Kidney Disease Surveillance System. Clin J Am Soc Nephrol. https:\/\/doi.org\/10.2215\/CJN.0000000867","journal-title":"Clin J Am Soc Nephrol"},{"key":"7384_CR7","doi-asserted-by":"publisher","first-page":"A8","DOI":"10.1053\/j.ajkd.2025.02.602","volume":"85","author":"KL Johansen","year":"2025","unstructured":"Johansen KL, Gilbertson DT, Li S, Li S, Liu J, Roetker NS, Hart A, Knapp CD, Ku E, Powe NR, Snyder J, Peter WS, Weinhandl ED, Wetmore JB (2025) US Renal Data System 2024 Annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis 85:A8-a11","journal-title":"Am J Kidney Dis"},{"key":"7384_CR8","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1007\/s00467-022-05816-7","volume":"38","author":"J Harambat","year":"2023","unstructured":"Harambat J, Madden I (2023) What is the true burden of chronic kidney disease in children worldwide? Pediatr Nephrol 38:1389\u20131393","journal-title":"Pediatr Nephrol"},{"key":"7384_CR9","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1093\/ndt\/gfad269","volume":"39","author":"WM Zhao","year":"2024","unstructured":"Zhao WM, Li XL, Shi R, Zhu Y, Wang ZJ, Wang XR, Pan HF, Wang DG (2024) Global, regional and national burden of CKD in children and adolescents from 1990 to 2019. Nephrol Dial Transplant 39:1268\u20131278","journal-title":"Nephrol Dial Transplant"},{"key":"7384_CR10","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s00467-011-1939-1","volume":"27","author":"J Harambat","year":"2012","unstructured":"Harambat J, van Stralen KJ, Kim JJ, Tizard EJ (2012) Epidemiology of chronic kidney disease in children. Pediatr Nephrol 27:363\u2013373","journal-title":"Pediatr Nephrol"},{"key":"7384_CR11","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s00467-021-05145-1","volume":"37","author":"R Harada","year":"2022","unstructured":"Harada R, Hamasaki Y, Okuda Y, Hamada R, Ishikura K (2022) Epidemiology of pediatric chronic kidney disease\/kidney failure: learning from registries and cohort studies. Pediatr Nephrol 37:1215\u20131229","journal-title":"Pediatr Nephrol"},{"key":"7384_CR12","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1053\/j.ajkd.2015.01.008","volume":"65","author":"BA Warady","year":"2015","unstructured":"Warady BA, Abraham AG, Schwartz GJ, Wong CS, Mu\u00f1oz A, Betoko A, Mitsnefes M, Kaskel F, Greenbaum LA, Mak RH, Flynn J, Moxey-Mims MM, Furth S (2015) Predictors of rapid progression of glomerular and nonglomerular kidney disease in children and adolescents: the chronic kidney disease in children (CKiD) Cohort. Am J Kidney Dis 65:878\u2013888","journal-title":"Am J Kidney Dis"},{"key":"7384_CR13","doi-asserted-by":"publisher","first-page":"e382","DOI":"10.1016\/S2214-109X(23)00570-3","volume":"12","author":"AK Bello","year":"2024","unstructured":"Bello AK, Okpechi IG, Levin A, Ye F, Damster S, Arruebo S, Donner JA, Caskey FJ, Cho Y, Davids MR, Davison SN, Htay H, Jha V, Lalji R, Malik C, Nangaku M, See E, Sozio SM, Tonelli M, Wainstein M, Yeung EK, Johnson DW (2024) An update on the global disparities in kidney disease burden and care across world countries and regions. Lancet Glob Health 12:e382\u2013e395","journal-title":"Lancet Glob Health"},{"key":"7384_CR14","volume-title":"Chronic kidney disease in the United States, 2023","author":"Prevention CfDCa","year":"2023","unstructured":"Centers for Disease Control and Prevention\u00a0(2023) Chronic kidney disease in the United States, 2023. US Department of Health and Human Services, Centers for Disease Control and Prevention"},{"key":"7384_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1563246","volume":"16","author":"MJ Li","year":"2025","unstructured":"Li MJ, Liu HY, Zhang YQ, Li SR, Zhang JH, Li R (2025) Global burden of chronic kidney disease and its attributable risk factors (1990-2021): an analysis based on the Global Burden of Disease Study. Front Endocrinol (Lausanne) 16:1563246","journal-title":"Front Endocrinol (Lausanne)"},{"key":"7384_CR16","doi-asserted-by":"publisher","first-page":"940","DOI":"10.2215\/CJN.01510218","volume":"13","author":"BI Freedman","year":"2018","unstructured":"Freedman BI, Moxey-Mims M (2018) The APOL1 long-term kidney transplantation outcomes network-APOLLO. Clin J Am Soc Nephrol 13:940\u2013942","journal-title":"Clin J Am Soc Nephrol"},{"key":"7384_CR17","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1038\/ng.226","volume":"40","author":"JB Kopp","year":"2008","unstructured":"Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW, Oleksyk T, McKenzie LM, Kajiyama H, Ahuja TS, Berns JS, Briggs W, Cho ME, Dart RA, Kimmel PL, Korbet SM, Michel DM, Mokrzycki MH, Schelling JR, Simon E, Trachtman H, Vlahov D, Winkler CA (2008) MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 40:1175\u20131184","journal-title":"Nat Genet"},{"key":"7384_CR18","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/ng.232","volume":"40","author":"WH Kao","year":"2008","unstructured":"Kao WH, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, Li M, Coresh J, Patterson N, Tandon A, Powe NR, Fink NE, Sadler JH, Weir MR, Abboud HE, Adler SG, Divers J, Iyengar SK, Freedman BI, Kimmel PL, Knowler WC, Kohn OF, Kramp K, Leehey DJ, Nicholas SB, Pahl MV, Schelling JR, Sedor JR, Thornley-Brown D, Winkler CA, Smith MW, Parekh RS (2008) MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 40:1185\u20131192","journal-title":"Nat Genet"},{"key":"7384_CR19","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1126\/science.1193032","volume":"329","author":"G Genovese","year":"2010","unstructured":"Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, Bowden DW, Langefeld CD, Oleksyk TK, Uscinski Knob AL, Bernhardy AJ, Hicks PJ, Nelson GW, Vanhollebeke B, Winkler CA, Kopp JB, Pays E, Pollak MR (2010) Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329:841\u2013845","journal-title":"Science"},{"key":"7384_CR20","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s00439-010-0861-0","volume":"128","author":"S Tzur","year":"2010","unstructured":"Tzur S, Rosset S, Shemer R, Yudkovsky G, Selig S, Tarekegn A, Bekele E, Bradman N, Wasser WG, Behar DM, Skorecki K (2010) Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 128:345\u2013350","journal-title":"Hum Genet"},{"key":"7384_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/cells14130960","volume":"14","author":"V H\u00f6ffken","year":"2025","unstructured":"H\u00f6ffken V, Braun DA, Pavenst\u00e4dt H, Weide T (2025) A cell biologist\u2019s view on APOL1: what we know and what we still need to address. Cells 14:960","journal-title":"Cells"},{"key":"7384_CR22","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1006\/geno.2001.6534","volume":"74","author":"NM Page","year":"2001","unstructured":"Page NM, Butlin DJ, Lomthaisong K, Lowry PJ (2001) The human apolipoprotein L gene cluster: identification, classification, and sites of distribution. Genomics 74:71\u201378","journal-title":"Genomics"},{"key":"7384_CR23","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1126\/science.1114566","volume":"309","author":"D P\u00e9rez-Morga","year":"2005","unstructured":"P\u00e9rez-Morga D, Vanhollebeke B, Paturiaux-Hanocq F, Nolan DP, Lins L, Hombl\u00e9 F, Vanhamme L, Tebabi P, Pays A, Poelvoorde P, Jacquet A, Brasseur R, Pays E (2005) Apolipoprotein L-I promotes trypanosome lysis by forming pores in lysosomal membranes. Science 309:469\u2013472","journal-title":"Science"},{"key":"7384_CR24","first-page":"257","volume":"6","author":"JR Franco","year":"2014","unstructured":"Franco JR, Simarro PP, Diarra A, Jannin JG (2014) Epidemiology of human African trypanosomiasis. Clin Epidemiol 6:257\u2013275","journal-title":"Clin Epidemiol"},{"key":"7384_CR25","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1111\/febs.13706","volume":"283","author":"AK Sharma","year":"2016","unstructured":"Sharma AK, Friedman DJ, Pollak MR, Alper SL (2016) Structural characterization of the C-terminal coiled-coil domains of wild-type and kidney disease-associated mutants of apolipoprotein L1. FEBS J 283:1846\u20131862","journal-title":"FEBS J"},{"key":"7384_CR26","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1053\/j.ackd.2014.06.005","volume":"21","author":"S Limou","year":"2014","unstructured":"Limou S, Nelson GW, Kopp JB, Winkler CA (2014) APOL1 kidney risk alleles: population genetics and disease associations. Adv Chronic Kidney Dis 21:426\u2013433","journal-title":"Adv Chronic Kidney Dis"},{"key":"7384_CR27","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1681\/ASN.2013010113","volume":"24","author":"MC Foster","year":"2013","unstructured":"Foster MC, Coresh J, Fornage M, Astor BC, Grams M, Franceschini N, Boerwinkle E, Parekh RS, Kao WH (2013) APOL1 variants associate with increased risk of CKD among African Americans. J Am Soc Nephrol 24:1484\u20131491","journal-title":"J Am Soc Nephrol"},{"key":"7384_CR28","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1681\/ASN.2011040388","volume":"22","author":"JB Kopp","year":"2011","unstructured":"Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, An P, Friedman D, Briggs W, Dart R, Korbet S, Mokrzycki MH, Kimmel PL, Limou S, Ahuja TS, Berns JS, Fryc J, Simon EE, Smith MC, Trachtman H, Michel DM, Schelling JR, Vlahov D, Pollak M, Winkler CA (2011) APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 22:2129\u20132137","journal-title":"J Am Soc Nephrol"},{"key":"7384_CR29","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1681\/ASN.2011040434","volume":"22","author":"N Papeta","year":"2011","unstructured":"Papeta N, Kiryluk K, Patel A, Sterken R, Kacak N, Snyder HJ, Imus PH, Mhatre AN, Lawani AK, Julian BA, Wyatt RJ, Novak J, Wyatt CM, Ross MJ, Winston JA, Klotman ME, Cohen DJ, Appel GB, D\u2019Agati VD, Klotman PE, Gharavi AG (2011) APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy. J Am Soc Nephrol 22:1991\u20131996","journal-title":"J Am Soc Nephrol"},{"key":"7384_CR30","doi-asserted-by":"crossref","unstructured":"Parsa A, Kao WH, Xie D, Astor BC, Li M, Hsu CY, Feldman HI, Parekh RS, Kusek JW, Greene TH, Fink JC, Anderson AH, Choi MJ, Wright JT Jr., Lash JP, Freedman BI, Ojo A, Winkler CA, Raj DS, Kopp JB, He J, Jensvold NG, Tao K, Lipkowitz MS, Appel LJ (2013) APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med 369:2183\u20132196","DOI":"10.1056\/NEJMoa1310345"},{"key":"7384_CR31","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2404211","volume":"392","author":"RA Gbadegesin","year":"2025","unstructured":"Gbadegesin RA, Ulasi I, Ajayi S, Raji Y, Olanrewaju T, Osafo C, Ademola AD, Asinobi A, Winkler CA, Burke D, Arogundade F, Ekem I, Plange-Rhule J, Mamven M, Matekole M, Amodu O, Cooper R, Antwi S, Adeyemo AA, Ilori TO, Adabayeri V, Nyarko A, Ghansah A, Amira T, Solarin A, Awobusuyi O, Kimmel PL, Brosius FC, Makusidi M, Odenigbo U, Kretzler M, Hodgin JB, Pollak MR, Boima V, Freedman BI, Palmer ND, Collins B, Phadnis M, Smith J, Agwai CI, Okoye O, Abdu A, Wilson J, Williams W, Salako BL, Parekh RS, Tayo B, Adu D, Ojo A (2025) APOL1 bi- and monoallelic variants and chronic kidney disease in West Africans. N Engl J Med 392:228\u2013238","journal-title":"N Engl J Med"},{"key":"7384_CR32","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41581-022-00538-3","volume":"18","author":"P Daneshpajouhnejad","year":"2022","unstructured":"Daneshpajouhnejad P, Kopp JB, Winkler CA, Rosenberg AZ (2022) The evolving story of apolipoprotein L1 nephropathy: the end of the beginning. Nat Rev Nephrol 18:307\u2013320","journal-title":"Nat Rev Nephrol"},{"key":"7384_CR33","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.jacc.2017.01.040","volume":"69","author":"GN Nadkarni","year":"2017","unstructured":"Nadkarni GN, Galarneau G, Ellis SB, Nadukuru R, Zhang J, Scott SA, Schurmann C, Li R, Rasmussen-Torvik LJ, Kho AN, Hayes MG, Pacheco JA, Manolio TA, Chisholm RL, Roden DM, Denny JC, Kenny EE, Bottinger EP (2017) Apolipoprotein L1 variants and blood pressure traits in African Americans. J Am Coll Cardiol 69:1564\u20131574","journal-title":"J Am Coll Cardiol"},{"key":"7384_CR34","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.ekir.2024.12.022","volume":"10","author":"KK Tassiopoulos","year":"2025","unstructured":"Tassiopoulos KK, Wu K, Wu Z, Overton ET, Palella FJ, Wyatt C, Kalayjian RC, Bruggeman LA (2025) APOL1 genotype and HIV infection: 20-year outcomes for CKD, cardiovascular disease, and hypertension. Kidney Int Rep 10:855\u2013865","journal-title":"Kidney Int Rep"},{"key":"7384_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2023.151314","volume":"42","author":"T Ilori","year":"2022","unstructured":"Ilori T, Watanabe A, Ng KH, Solarin A, Sinha A, Gbadegesin R (2022) Genetics of chronic kidney disease in low-resource settings. Semin Nephrol 42:151314","journal-title":"Semin Nephrol"},{"key":"7384_CR36","doi-asserted-by":"publisher","first-page":"603","DOI":"10.5301\/jn.5000179","volume":"25","author":"WG Wasser","year":"2012","unstructured":"Wasser WG, Tzur S, Wolday D, Adu D, Baumstein D, Rosset S, Skorecki K (2012) Population genetics of chronic kidney disease: the evolving story of APOL1. J Nephrol 25:603\u2013618","journal-title":"J Nephrol"},{"key":"7384_CR37","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1053\/j.ajkd.2018.06.020","volume":"72","author":"BI Freedman","year":"2018","unstructured":"Freedman BI, Limou S, Ma L, Kopp JB (2018) APOL1-associated nephropathy: a key contributor to racial disparities in CKD. Am J Kidney Dis 72:S8-s16","journal-title":"Am J Kidney Dis"},{"key":"7384_CR38","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1093\/ndt\/gfr796","volume":"27","author":"S Tzur","year":"2012","unstructured":"Tzur S, Rosset S, Skorecki K, Wasser WG (2012) APOL1 allelic variants are associated with lower age of dialysis initiation and thereby increased dialysis vintage in African and Hispanic Americans with non-diabetic end-stage kidney disease. Nephrol Dial Transplant 27:1498\u20131505","journal-title":"Nephrol Dial Transplant"},{"key":"7384_CR39","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1056\/NEJMc1800748","volume":"379","author":"GN Nadkarni","year":"2018","unstructured":"Nadkarni GN, Gignoux CR, Sorokin EP, Daya M, Rahman R, Barnes KC, Wassel CL, Kenny EE (2018) Worldwide frequencies of APOL1 renal risk variants. N Engl J Med 379:2571\u20132572","journal-title":"N Engl J Med"},{"key":"7384_CR40","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae397","volume":"18","author":"D Ben-Ruby","year":"2025","unstructured":"Ben-Ruby D, Atias-Varon D, Kagan M, Chowers G, Shlomovitz O, Slabodnik-Kaner K, Mano N, Avayou S, Atsmony Y, Levin D, Dotan E, Calderon-Margalit R, Shnaider A, Haviv YS, Birk OS, Hadar N, Anikster Y, Berar Yanay N, Chernin G, Kruzel-Davila E, Beckerman P, Rozen-Zvi B, Doctor GT, Stanescu HC, Shemer R, Pras E, Reznik-Wolf H, Nahum AH, Dominissini D, Skorecki K, Vivante A (2025) Multiethnic prevalence of the APOL1 G1 and G2 variants among the Israeli dialysis population. Clin Kidney J 18:sfae397","journal-title":"Clin Kidney J"},{"key":"7384_CR41","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.ekir.2019.04.002","volume":"4","author":"PM Ekulu","year":"2019","unstructured":"Ekulu PM, Nkoy AB, Betukumesu DK, Aloni MN, Makulo JRR, Sumaili EK, Mafuta EM, Elmonem MA, Arcolino FO, Kitetele FN, Lepira FB, van den Heuvel LP, Levtchenko EN (2019) APOL1 risk genotypes are associated with early kidney damage in children in Sub-Saharan Africa. Kidney Int Rep 4:930\u2013938","journal-title":"Kidney Int Rep"},{"key":"7384_CR42","doi-asserted-by":"crossref","unstructured":"Purswani MU, Patel K, Winkler CA, Spector SA, Hazra R, Seage GR 3rd, Mofenson L, Karalius B, Scott GB, Van Dyke RB, Kopp JB (2016) Brief report: APOL1 renal risk variants are associated with chronic kidney disease in children and youth with perinatal HIV infection. J Acquir Immune Defic Syndr 73:63\u201368","DOI":"10.1097\/QAI.0000000000001010"},{"key":"7384_CR43","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3389\/fped.2016.00122","volume":"4","author":"RP Woroniecki","year":"2016","unstructured":"Woroniecki RP, Ng DK, Limou S, Winkler CA, Reidy KJ, Mitsnefes M, Sampson MG, Wong CS, Warady BA, Furth SL, Kopp JB, Kaskel FJ (2016) Renal and cardiovascular morbidities associated with APOL1 status among African-American and Non-African-American children with focal segmental glomerulosclerosis. Front Pediatr 4:122","journal-title":"Front Pediatr"},{"key":"7384_CR44","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1053\/j.ajkd.2017.10.013","volume":"71","author":"A Adeyemo","year":"2018","unstructured":"Adeyemo A, Esezobor C, Solarin A, Abeyagunawardena A, Kari JA, El Desoky S, Greenbaum LA, Kamel M, Kallash M, Silva C, Young A, Hunley TE, de Jesus-Gonzalez N, Srivastava T, Gbadegesin R (2018) HLA-DQA1 and APOL1 as risk loci for childhood-onset steroid-sensitive and steroid-resistant nephrotic syndrome. Am J Kidney Dis 71:399\u2013406","journal-title":"Am J Kidney Dis"},{"key":"7384_CR45","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1093\/ndt\/gfw061","volume":"32","author":"DK Ng","year":"2017","unstructured":"Ng DK, Robertson CC, Woroniecki RP, Limou S, Gillies CE, Reidy KJ, Winkler CA, Hingorani S, Gibson KL, Hjorten R, Sethna CB, Kopp JB, Moxey-Mims M, Furth SL, Warady BA, Kretzler M, Sedor JR, Kaskel FJ, Sampson MG (2017) APOL1-associated glomerular disease among African-American children: a collaboration of the Chronic Kidney Disease in Children (CKiD) and Nephrotic Syndrome Study Network (NEPTUNE) cohorts. Nephrol Dial Transplant 32:983\u2013990","journal-title":"Nephrol Dial Transplant"},{"key":"7384_CR46","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1681\/ASN.2013070700","volume":"25","author":"LA Bruggeman","year":"2014","unstructured":"Bruggeman LA, O\u2019Toole JF, Ross MD, Madhavan SM, Smurzynski M, Wu K, Bosch RJ, Gupta S, Pollak MR, Sedor JR, Kalayjian RC (2014) Plasma apolipoprotein L1 levels do not correlate with CKD. J Am Soc Nephrol 25:634\u2013644","journal-title":"J Am Soc Nephrol"},{"key":"7384_CR47","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1681\/ASN.2015101121","volume":"27","author":"J Kozlitina","year":"2016","unstructured":"Kozlitina J, Zhou H, Brown PN, Rohm RJ, Pan Y, Ayanoglu G, Du X, Rimmer E, Reilly DF, Roddy TP, Cully DF, Vogt TF, Blom D, Hoek M (2016) Plasma levels of risk-variant APOL1 do not associate with renal disease in a population-based cohort. J Am Soc Nephrol 27:3204\u20133219","journal-title":"J Am Soc Nephrol"},{"key":"7384_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0152775","volume":"11","author":"CR Dorr","year":"2016","unstructured":"Dorr CR, Freedman BI, Hicks PJ, Brown WM, Russell GB, Julian BA, Pastan SO, Gautreaux MD, Muthusamy A, Chinnakotla S, Hauptfeld V, Bray RA, Kirk AD, Divers J, Israni AK (2016) Deceased-donor apolipoprotein L1 renal-risk variants have minimal effects on liver transplant outcomes. PLoS One 11:e0152775","journal-title":"PLoS ONE"},{"key":"7384_CR49","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1194\/jlr.M059733","volume":"56","author":"D Cheng","year":"2015","unstructured":"Cheng D, Weckerle A, Yu Y, Ma L, Zhu X, Murea M, Freedman BI, Parks JS, Shelness GS (2015) Biogenesis and cytotoxicity of APOL1 renal risk variant proteins in hepatocytes and hepatoma cells. J Lipid Res 56:1583\u20131593","journal-title":"J Lipid Res"},{"key":"7384_CR50","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1016\/j.immuni.2021.10.004","volume":"54","author":"J Wu","year":"2021","unstructured":"Wu J, Ma Z, Raman A, Beckerman P, Dhillon P, Mukhi D, Palmer M, Chen HC, Cohen CR, Dunn T, Reilly J, Meyer N, Shashaty M, Arany Z, Hask\u00f3 G, Laudanski K, Hung A, Susztak K (2021) APOL1 risk variants in individuals of African genetic ancestry drive endothelial cell defects that exacerbate sepsis. Immunity 54:2632-2649.e2636","journal-title":"Immunity"},{"key":"7384_CR51","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1681\/ASN.2020070954","volume":"31","author":"E Pays","year":"2020","unstructured":"Pays E (2020) The mechanism of kidney disease due to APOL1 risk variants. J Am Soc Nephrol 31:2502\u20132505","journal-title":"J Am Soc Nephrol"},{"key":"7384_CR52","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1681\/ASN.2011010069","volume":"22","author":"SM Madhavan","year":"2011","unstructured":"Madhavan SM, O\u2019Toole JF, Konieczkowski M, Ganesan S, Bruggeman LA, Sedor JR (2011) APOL1 localization in normal kidney and nondiab-etic kidney disease. J Am Soc Nephrol 22:2119\u20132128","journal-title":"J Am Soc Nephrol"},{"key":"7384_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051546","volume":"7","author":"DB Johnstone","year":"2012","unstructured":"Johnstone DB, Shegokar V, Nihalani D, Rathore YS, Mallik L, Ashish ZV, Ikizler HO, Powar R, Holzman LB (2012) APOL1 null alleles from a rural village in India do not correlate with glomerulosclerosis. PLoS One 7:e51546","journal-title":"PLoS ONE"},{"key":"7384_CR54","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1681\/ASN.0000000688","volume":"36","author":"X Zhang","year":"2025","unstructured":"Zhang X, Scadden AW, Marthi A, Buchanan VL, Qu Y, Ferrier KR, Chen BD, Graff M, Avila J, Boerwinkle E, Buyske S, Clish CB, Cruz D, Fornage M, Gerzsten RE, Gignoux CR, Glover L, Hou L, Justice AE, Kooperberg C, Kramer H, Lange L, Loos RJF, Matise T, Mychaleckyj JC, Olabisi OA, Peters U, Raffield LM, Reiner AP, Rich SS, Rotter JI, Taylor KD, Yu B, Zheng Y, North KE, Mottl AK, Highland HM, Stanislawski MA (2025) Alterations in DNA methylation, proteomic, and metabolomic profiles in African ancestry populations with APOL1 risk alleles. J Am Soc Nephrol 36:1490\u20131504","journal-title":"J Am Soc Nephrol"},{"key":"7384_CR55","doi-asserted-by":"publisher","DOI":"10.1172\/JCI172262","volume":"134","author":"S Datta","year":"2024","unstructured":"Datta S, Antonio BM, Zahler NH, Theile JW, Krafte D, Zhang H, Rosenberg PB, Chaves AB, Muoio DM, Zhang G, Silas D, Li G, Soldano K, Nystrom S, Ferreira D, Miller SE, Bain JR, Muehlbauer MJ, Ilkayeva O, Becker TC, Hohmeier HE, Newgard CB, Olabisi OA (2024) APOL1-mediated monovalent cation transport contributes to APOL1-mediated podocytopathy in kidney disease. J Clin Invest 134:e172262","journal-title":"J Clin Invest"},{"key":"7384_CR56","doi-asserted-by":"crossref","unstructured":"Olabisi OA, Zhang JY, VerPlank L, Zahler N, DiBartolo S 3rd, Heneghan JF, Schl\u00f6ndorff JS, Suh JH, Yan P, Alper SL, Friedman DJ, Pollak MR (2016) APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases. Proc Natl Acad Sci U S A 113:830\u2013837","DOI":"10.1073\/pnas.1522913113"},{"key":"7384_CR57","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/ki.2014.270","volume":"87","author":"B Nichols","year":"2015","unstructured":"Nichols B, Jog P, Lee JH, Blackler D, Wilmot M, D\u2019Agati V, Markowitz G, Kopp JB, Alper SL, Pollak MR, Friedman DJ (2015) Innate immunity pathways regulate the nephropathy gene Apolipoprotein L1. Kidney Int 87:332\u2013342","journal-title":"Kidney Int"},{"key":"7384_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43020-9","volume":"14","author":"Y Gupta","year":"2023","unstructured":"Gupta Y, Friedman DJ, McNulty MT, Khan A, Lane B, Wang C, Ke J, Jin G, Wooden B, Knob AL, Lim TY, Appel GB, Huggins K, Liu L, Mitrotti A, Stangl MC, Bomback A, Westland R, Bodria M, Marasa M, Shang N, Cohen DJ, Crew RJ, Morello W, Canetta P, Radhakrishnan J, Martino J, Liu Q, Chung WK, Espinoza A, Luo Y, Wei WQ, Feng Q, Weng C, Fang Y, Kullo IJ, Naderian M, Limdi N, Irvin MR, Tiwari H, Mohan S, Rao M, Dube GK, Chaudhary NS, Guti\u00e9rrez OM, Judd SE, Cushman M, Lange LA, Lange EM, Bivona DL, Verbitsky M, Winkler CA, Kopp JB, Santoriello D, Batal I, Pinheiro SVB, Oliveira EA, Simoes ESAC, Pisani I, Fiaccadori E, Lin F, Gesualdo L, Amoroso A, Ghiggeri GM, D\u2019Agati VD, Magistroni R, Kenny EE, Loos RJF, Montini G, Hildebrandt F, Paul DS, Petrovski S, Goldstein DB, Kretzler M, Gbadegesin R, Gharavi AG, Kiryluk K, Sampson MG, Pollak MR, Sanna-Cherchi S (2023) Strong protective effect of the APOL1 p.N264K variant against G2-associated focal segmental glomerulosclerosis and kidney disease. Nat Commun 14:7836","journal-title":"Nat Commun"},{"key":"7384_CR59","doi-asserted-by":"publisher","DOI":"10.1093\/g3journal\/jkae290","volume":"15","author":"CA Simeone","year":"2025","unstructured":"Simeone CA, McNulty MT, Gupta Y, Genovese G, Sampson MG, Sanna-Cherchi S, Friedman DJ, Pollak MR (2025) The APOL1 p.N264K variant is co-inherited with the G2 kidney disease risk variant through a proximity recombination event. G3 (Bethesda) 15:jkae290","journal-title":"G3 (Bethesda)"},{"key":"7384_CR60","first-page":"43","volume":"4","author":"R Gbadegesin","year":"2024","unstructured":"Gbadegesin R, Martinelli E, Gupta Y, Friedman DJ, Sampson MG, Pollak MR, Sanna-Cherchi S (2024) APOL1 genotyping is incomplete without testing for the protective M1 modifier p. N264K variant. Glomerular Dis 4:43\u201348","journal-title":"Glomerular Dis"},{"key":"7384_CR61","doi-asserted-by":"publisher","first-page":"e02198","DOI":"10.1128\/mBio.02198-15","volume":"7","author":"B Cuypers","year":"2016","unstructured":"Cuypers B, Lecordier L, Meehan CJ, Van den Broeck F, Imamura H, B\u00fcscher P, Dujardin JC, Laukens K, Schnaufer A, Dewar C, Lewis M, Balmer O, Azurago T, Kyei-Faried S, Ohene SA, Duah B, Homiah P, Mensah EK, Anleah F, Franco JR, Pays E, Deborggraeve S (2016) Apolipoprotein L1 variant associated with increased susceptibility to trypanosome infection. mBio 7:e02198-02115","journal-title":"mBio"},{"key":"7384_CR62","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1073\/pnas.1716113115","volume":"115","author":"JY Zhang","year":"2018","unstructured":"Zhang JY, Wang M, Tian L, Genovese G, Yan P, Wilson JG, Thadhani R, Mottl AK, Appel GB, Bick AG, Sampson MG, Alper SL, Friedman DJ, Pollak MR (2018) UBD modifies APOL1-induced kidney disease risk. Proc Natl Acad Sci U S A 115:3446\u20133451","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7384_CR63","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1681\/ASN.2014111131","volume":"27","author":"MG Sampson","year":"2016","unstructured":"Sampson MG, Robertson CC, Martini S, Mariani LH, Lemley KV, Gillies CE, Otto EA, Kopp JB, Randolph A, Vega-Warner V, Eichinger F, Nair V, Gipson DS, Cattran DC, Johnstone DB, O\u2019Toole JF, Bagnasco SM, Song PX, Barisoni L, Troost JP, Kretzler M, Sedor JR (2016) Integrative genomics identifies novel associations with APOL1 risk genotypes in Black NEPTUNE subjects. J Am Soc Nephrol 27:814\u2013823","journal-title":"J Am Soc Nephrol"},{"key":"7384_CR64","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1093\/ndt\/gfw451","volume":"33","author":"KL Skorecki","year":"2018","unstructured":"Skorecki KL, Lee JH, Langefeld CD, Rosset S, Tzur S, Wasser WG, Shemer R, Hawkins GA, Divers J, Parekh RS, Li M, Sampson MG, Kretzler M, Pollak MR, Shah S, Blackler D, Nichols B, Wilmot M, Alper SL, Freedman BI, Friedman DJ (2018) A null variant in the apolipoprotein L3 gene is associated with non-diabetic nephropathy. Nephrol Dial Transplant 33:323\u2013330","journal-title":"Nephrol Dial Transplant"},{"key":"7384_CR65","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1016\/j.celrep.2020.02.064","volume":"30","author":"S Uzureau","year":"2020","unstructured":"Uzureau S, Lecordier L, Uzureau P, Hennig D, Graversen JH, Hombl\u00e9 F, Mfutu PE, Oliveira Arcolino F, Ramos AR, La Rovere RM, Luyten T, Vermeersch M, Tebabi P, Dieu M, Cuypers B, Deborggraeve S, Rabant M, Legendre C, Moestrup SK, Levtchenko E, Bultynck G, Erneux C, P\u00e9rez-Morga D, Pays E (2020) APOL1 C-terminal variants may trigger kidney disease through interference with APOL3 control of actomyosin. Cell Rep 30:3821-3836.e3813","journal-title":"Cell Rep"},{"key":"7384_CR66","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.181238","volume":"9","author":"DY Zhang","year":"2024","unstructured":"Zhang DY, Levin MG, Duda JT, Landry LG, Witschey WR, Damrauer SM, Ritchie MD, Rader DJ (2024) Protein-truncating variant in APOL3 increases chronic kidney disease risk in epistasis with APOL1 risk alleles. JCI Insight 9:e181238","journal-title":"JCI Insight"},{"key":"7384_CR67","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.semnephrol.2015.04.008","volume":"35","author":"PD Dummer","year":"2015","unstructured":"Dummer PD, Limou S, Rosenberg AZ, Heymann J, Nelson G, Winkler CA, Kopp JB (2015) APOL1 kidney disease risk variants: an evolving landscape. Semin Nephrol 35:222\u2013236","journal-title":"Semin Nephrol"},{"key":"7384_CR68","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1681\/ASN.2020050558","volume":"31","author":"H Wu","year":"2020","unstructured":"Wu H, Larsen CP, Hernandez-Arroyo CF, Mohamed MMB, Caza T, Sharshir M, Chughtai A, Xie L, Gimenez JM, Sandow TA, Lusco MA, Yang H, Acheampong E, Rosales IA, Colvin RB, Fogo AB, Velez JCQ (2020) AKI and collapsing glomerulopathy associated with COVID-19 and APOL 1 high-risk genotype. J Am Soc Nephrol 31:1688\u20131695","journal-title":"J Am Soc Nephrol"},{"key":"7384_CR69","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.molmed.2018.05.008","volume":"24","author":"P Beckerman","year":"2018","unstructured":"Beckerman P, Susztak K (2018) APOL1: the balance imposed by infection, selection, and kidney disease. Trends Mol Med 24:682\u2013695","journal-title":"Trends Mol Med"},{"key":"7384_CR70","doi-asserted-by":"publisher","DOI":"10.1172\/JCI136329","volume":"131","author":"J Wu","year":"2021","unstructured":"Wu J, Raman A, Coffey NJ, Sheng X, Wahba J, Seasock MJ, Ma Z, Beckerman P, Laczk\u00f3 D, Palmer MB, Kopp JB, Kuo JJ, Pullen SS, Boustany-Kari CM, Linkermann A, Susztak K (2021) The key role of NLRP3 and STING in APOL1-associated podocytopathy. J Clin Invest 131:e136329","journal-title":"J Clin Invest"},{"key":"7384_CR71","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.kint.2025.05.017","volume":"108","author":"AO Ojo","year":"2025","unstructured":"Ojo AO, Adu D, Bramham K, Freedman BI, Gbadegesin RA, Ilori TO, Jefferson N, Olabisi OA, Susztak K, Young BA, Cheung M, King JM, Grams ME, Jadoul M, Ulasi II, Conference Participants (2025) APOL1 kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. Kidney Int 108:763\u2013779","journal-title":"Kidney Int"},{"key":"7384_CR72","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.kint.2025.09.025","volume":"109","author":"BI Freedman","year":"2026","unstructured":"Freedman BI, Gillespie BS, Egbuna OI (2026) ICD-10 codes for APOL1-mediated kidney disease. Kidney Int 109:238\u2013241","journal-title":"Kidney Int"},{"key":"7384_CR73","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1681\/ASN.2013111242","volume":"26","author":"JB Kopp","year":"2015","unstructured":"Kopp JB, Winkler CA, Zhao X, Radeva MK, Gassman JJ, D\u2019Agati VD, Nast CC, Wei C, Reiser J, Guay-Woodford LM, Pollak MR, Hildebrandt F, Moxey-Mims M, Gipson DS, Trachtman H, Friedman AL, Kaskel FJ (2015) Clinical features and histology of apolipoprotein L1-associated nephropathy in the FSGS clinical trial. J Am Soc Nephrol 26:1443\u20131448","journal-title":"J Am Soc Nephrol"},{"key":"7384_CR74","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1681\/ASN.2014050469","volume":"26","author":"AN Kasembeli","year":"2015","unstructured":"Kasembeli AN, Duarte R, Ramsay M, Mosiane P, Dickens C, Dix-Peek T, Limou S, Sezgin E, Nelson GW, Fogo AB, Goetsch S, Kopp JB, Winkler CA, Naicker S (2015) APOL1 risk variants are strongly associated with HIV-associated nephropathy in Black South Africans. J Am Soc Nephrol 26:2882\u20132890","journal-title":"J Am Soc Nephrol"},{"key":"7384_CR75","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1093\/ndt\/gfx368","volume":"33","author":"BI Freedman","year":"2018","unstructured":"Freedman BI, Kistler AL, Skewes-Cox P, Ganem D, Spainhour M, Turner J, Divers J, Langefeld CD, Murea M, Hicks PJ, Hemal AK, Snipes JA, Zhao L, Abend JR, Lyles DS, Ma L, Skorecki KL (2018) JC polyoma viruria associates with protection from chronic kidney disease independently from apolipoprotein L1 genotype in African Americans. Nephrol Dial Transplant 33:1960\u20131967","journal-title":"Nephrol Dial Transplant"},{"key":"7384_CR76","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/MNH.0000000000000464","volume":"28","author":"J Divers","year":"2019","unstructured":"Divers J, Langefeld CD, Lyles DS, Ma L, Freedman BI (2019) Protective association between JC polyoma viruria and kidney disease. Curr Opin Nephrol Hypertens 28:65\u201369","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"7384_CR77","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/MNH.0000000000001068","volume":"34","author":"MR Pollak","year":"2025","unstructured":"Pollak MR, Friedman DJ (2025) APOL1-associated kidney disease: modulators of the genotype-phenotype relationship. Curr Opin Nephrol Hypertens 34:191\u2013198","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"7384_CR78","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.157432","volume":"7","author":"SE Nystrom","year":"2022","unstructured":"Nystrom SE, Li G, Datta S, Soldano KL, Silas D, Weins A, Hall G, Thomas DB, Olabisi OA (2022) JAK inhibitor blocks COVID-19 cytokine-induced JAK\/STAT\/APOL1 signaling in glomerular cells and podocytopathy in human kidney organoids. JCI Insight 7:e157432","journal-title":"JCI Insight"},{"key":"7384_CR79","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.2215\/CJN.01070121","volume":"16","author":"CP Larsen","year":"2021","unstructured":"Larsen CP, Wickman TJ, Braga JR, Matute-Trochez LA, Hasty AE, Buckner LR, Arthur JM, Haun RS, Velez JCQ (2021) APOL1 risk variants and acute kidney injury in Black Americans with COVID-19. Clin J Am Soc Nephrol 16:1790\u20131796","journal-title":"Clin J Am Soc Nephrol"},{"key":"7384_CR80","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.3899\/jrheum.190684","volume":"47","author":"G Vajgel","year":"2020","unstructured":"Vajgel G, Lima SC, Santana DJS, Oliveira CBL, Costa DMN, Hicks PJ, Cavalcante M, Langefeld CD, Valente LM, Crovella S, Kirsztajn GM, Freedman BI, Sandrin-Garcia P (2020) Effect of a single apolipoprotein L1 gene nephropathy variant on the risk of advanced lupus nephritis in Brazilians. J Rheumatol 47:1209\u20131217","journal-title":"J Rheumatol"},{"key":"7384_CR81","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1001\/jamainternmed.2021.8538","volume":"182","author":"AM Hung","year":"2022","unstructured":"Hung AM, Shah SC, Bick AG, Yu Z, Chen HC, Hunt CM, Wendt F, Wilson O, Greevy RA, Chung CP, Suzuki A, Ho YL, Akwo E, Polimanti R, Zhou J, Reaven P, Tsao PS, Gaziano JM, Huffman JE, Joseph J, Luoh SW, Iyengar S, Chang KM, Casas JP, Matheny ME, O\u2019Donnell CJ, Cho K, Tao R, Susztak K, Robinson-Cohen C, Tuteja S, Siew ED (2022) APOL1 risk variants, acute kidney injury, and death in participants with African ancestry hospitalized with COVID-19 from the Million Veteran Program. JAMA Intern Med 182:386\u2013395","journal-title":"JAMA Intern Med"},{"key":"7384_CR82","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1159\/000529227","volume":"3","author":"MR Pollak","year":"2023","unstructured":"Pollak MR, Friedman DJ (2023) APOL1 and APOL1-associated kidney disease: a common disease, an unusual disease gene - Proceedings of the Henry Shavelle Professorship. Glomerular Dis 3:75\u201387","journal-title":"Glomerular Dis"},{"key":"7384_CR83","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/art.38220","volume":"66","author":"BI Freedman","year":"2014","unstructured":"Freedman BI, Langefeld CD, Andringa KK, Croker JA, Williams AH, Garner NE, Birmingham DJ, Hebert LA, Hicks PJ, Segal MS, Edberg JC, Brown EE, Alarc\u00f3n GS, Costenbader KH, Comeau ME, Criswell LA, Harley JB, James JA, Kamen DL, Lim SS, Merrill JT, Sivils KL, Niewold TB, Patel NM, Petri M, Ramsey-Goldman R, Reveille JD, Salmon JE, Tsao BP, Gibson KL, Byers JR, Vinnikova AK, Lea JP, Julian BA, Kimberly RP (2014) End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol 66:390\u2013396","journal-title":"Arthritis Rheumatol"},{"key":"7384_CR84","doi-asserted-by":"publisher","first-page":"e385","DOI":"10.3324\/haematol.2018.212779","volume":"104","author":"RS Zahr","year":"2019","unstructured":"Zahr RS, Rampersaud E, Kang G, Weiss MJ, Wu G, Davis RL, Hankins JS, Estepp JH, Lebensburger J (2019) Children with sickle cell anemia and APOL1 genetic variants develop albuminuria early in life. Haematologica 104:e385\u2013e387","journal-title":"Haematologica"},{"key":"7384_CR85","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.xkme.2021.05.004","volume":"3","author":"BA Young","year":"2021","unstructured":"Young BA, Wilson JG, Reiner A, Kestenbaum B, Franceschini N, Bansal N, Correa A, Himmelfarb J, Katz R (2021) APOL1, sickle cell trait, and CKD in the Jackson Heart Study. Kidney Med 3:962-973.e961","journal-title":"Kidney Med"},{"key":"7384_CR86","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/bjh.14842","volume":"179","author":"R Kormann","year":"2017","unstructured":"Kormann R, Jannot AS, Narjoz C, Ribeil JA, Manceau S, Delville M, Joste V, Pri\u00e9 D, Pouchot J, Thervet E, Courbebaisse M, Arlet JB (2017) Roles of APOL1 G1 and G2 variants in sickle cell disease patients: Kidney is the main target. Br J Haematol 179:323\u2013335","journal-title":"Br J Haematol"},{"key":"7384_CR87","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/bjh.17832","volume":"196","author":"OC Adebayo","year":"2022","unstructured":"Adebayo OC, Betukumesu DK, Nkoy AB, Adesoji OM, Ekulu PM, Van den Heuvel LP, Levtchenko EN, Labarque V (2022) Clinical and genetic factors are associated with kidney complications in African children with sickle cell anaemia. Br J Haematol 196:204\u2013214","journal-title":"Br J Haematol"},{"key":"7384_CR88","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1681\/ASN.2019020152","volume":"30","author":"M Wang","year":"2019","unstructured":"Wang M, Chun J, Genovese G, Knob AU, Benjamin A, Wilkins MS, Friedman DJ, Appel GB, Lifton RP, Mane S, Pollak MR (2019) Contributions of rare gene variants to familial and sporadic FSGS. J Am Soc Nephrol 30:1625\u20131640","journal-title":"J Am Soc Nephrol"},{"key":"7384_CR89","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/bjh.14724","volume":"178","author":"A Geard","year":"2017","unstructured":"Geard A, Pule GD, ChetchaChemegni B, Ngo Bitoungui VJ, Kengne AP, Chimusa ER, Wonkam A (2017) Clinical and genetic predictors of renal dysfunctions in sickle cell anaemia in Cameroon. Br J Haematol 178:629\u2013639","journal-title":"Br J Haematol"},{"key":"7384_CR90","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1159\/000494581","volume":"47","author":"KO Olaniran","year":"2019","unstructured":"Olaniran KO, Eneanya ND, Nigwekar SU, Vela-Parada XF, Achebe MM, Sharma A, Thadhani RI (2019) Sickle cell nephropathy in the pediatric population. Blood Purif 47:205\u2013213","journal-title":"Blood Purif"},{"key":"7384_CR91","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3390\/biom15020205","volume":"15","author":"PC Singhal","year":"2025","unstructured":"Singhal PC, Skorecki K (2025) APOL1 dynamics in diabetic kidney disease and hypertension. Biomolecules 15:205","journal-title":"Biomolecules"},{"key":"7384_CR92","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1111\/j.1600-6143.2011.03513.x","volume":"11","author":"AM Reeves-Daniel","year":"2011","unstructured":"Reeves-Daniel AM, DePalma JA, Bleyer AJ, Rocco MV, Murea M, Adams PL, Langefeld CD, Bowden DW, Hicks PJ, Stratta RJ, Lin JJ, Kiger DF, Gautreaux MD, Divers J, Freedman BI (2011) The APOL1 gene and allograft survival after kidney transplantation. Am J Transplant 11:1025\u20131030","journal-title":"Am J Transplant"},{"key":"7384_CR93","doi-asserted-by":"publisher","DOI":"10.1172\/JCI146643","volume":"131","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Sun Z, Fu J, Lin Q, Banu K, Chauhan K, Planoutene M, Wei C, Salem F, Yi Z, Liu R, Cravedi P, Cheng H, Hao K, O\u2019Connell PJ, Ishibe S, Zhang W, Coca SG, Gibson IW, Colvin RB, He JC, Heeger PS, Murphy B, Menon MC (2021) Recipient APOL1 risk alleles associate with death-censored renal allograft survival and rejection episodes. J Clin Invest 131:e146643","journal-title":"J Clin Invest"},{"key":"7384_CR94","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1681\/ASN.2017060658","volume":"29","author":"MD Doshi","year":"2018","unstructured":"Doshi MD, Ortigosa-Goggins M, Garg AX, Li L, Poggio ED, Winkler CA, Kopp JB (2018) APOL1 genotype and renal function of Black living donors. J Am Soc Nephrol 29:1309\u20131316","journal-title":"J Am Soc Nephrol"},{"key":"7384_CR95","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1681\/ASN.2020101399","volume":"32","author":"BI Freedman","year":"2021","unstructured":"Freedman BI, Burke W, Divers J, Eberhard L, Gadegbeku CA, Gbadegesin R, Hall ME, Jones-Smith T, Knight R, Kopp JB, Kovesdy CP, Norris KC, Olabisi OA, Roberts GV, Sedor JR, Blacksher E (2021) Diagnosis, education, and care of patients with APOL1-associated nephropathy: a Delphi consensus and systematic review. J Am Soc Nephrol 32:1765\u20131778","journal-title":"J Am Soc Nephrol"},{"key":"7384_CR96","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1097\/TP.0000000000003641","volume":"105","author":"MD Doshi","year":"2021","unstructured":"Doshi MD, Gordon EJ, Freedman BI, Glover C, Locke JE, Thomas CP (2021) Integrating APOL1 kidney-risk variant testing in live kidney donor evaluation: an expert panel opinion. Transplantation 105:2132\u20132134","journal-title":"Transplantation"},{"key":"7384_CR97","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.ekir.2019.11.022","volume":"5","author":"BI Freedman","year":"2020","unstructured":"Freedman BI, Moxey-Mims MM, Alexander AA, Astor BC, Birdwell KA, Bowden DW, Bowen G, Bromberg J, Craven TE, Dadhania DM, Divers J, Doshi MD, Eidbo E, Fornoni A, Gautreaux MD, Gbadegesin RA, Gee PO, Guerra G, Hsu CY, Iltis AS, Jefferson N, Julian BA, Klassen DK, Koty PP, Langefeld CD, Lentine KL, Ma L, Mannon RB, Menon MC, Mohan S, Moore JB, Murphy B, Newell KA, Odim J, Ortigosa-Goggins M, Palmer ND, Park M, Parsa A, Pastan SO, Poggio ED, Rajapakse N, Reeves-Daniel AM, Rosas SE, Russell LP, Sawinski D, Smith SC, Spainhour M, Stratta RJ, Weir MR, Reboussin DM, Kimmel PL, Brennan DC (2020) APOL1 long-term kidney transplantation outcomes network (APOLLO): design and rationale. Kidney Int Rep 5:278\u2013288","journal-title":"Kidney Int Rep"},{"key":"7384_CR98","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1111\/petr.12766","volume":"20","author":"I Guan","year":"2016","unstructured":"Guan I, Singer P, Frank R, Chorny N, Infante L, Sethna CB (2016) Role of race in kidney transplant outcomes in children with focal segmental glomerulosclerosis. Pediatr Transplant 20:790\u2013797","journal-title":"Pediatr Transplant"},{"key":"7384_CR99","doi-asserted-by":"crossref","unstructured":"Ito K, Bick AG, Flannick J, Friedman DJ, Genovese G, Parfenov MG, Depalma SR, Gupta N, Gabriel SB, Taylor HA Jr., Fox ER, Newton-Cheh C, Kathiresan S, Hirschhorn JN, Altshuler DM, Pollak MR, Wilson JG, Seidman JG, Seidman C (2014) Increased burden of cardiovascular disease in carriers of APOL1 genetic variants. Circ Res 114:845\u2013850","DOI":"10.1161\/CIRCRESAHA.114.302347"},{"key":"7384_CR100","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.117.002098","volume":"11","author":"OM Guti\u00e9rrez","year":"2018","unstructured":"Guti\u00e9rrez OM, Irvin MR, Chaudhary NS, Cushman M, Zakai NA, David VA, Limou S, Pamir N, Reiner AP, Naik RP, Sale MM, Safford MM, Hyacinth HI, Judd SE, Kopp JB, Winkler CA (2018) APOL1 nephropathy risk variants and incident cardiovascular disease events in community-dwelling Black adults. Circ Genom Precis Med 11:e002098","journal-title":"Circ Genom Precis Med"},{"key":"7384_CR101","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1161\/ATVBAHA.115.305970","volume":"36","author":"KJ Mukamal","year":"2016","unstructured":"Mukamal KJ, Tremaglio J, Friedman DJ, Ix JH, Kuller LH, Tracy RP, Pollak MR (2016) APOL1 genotype, kidney and cardiovascular disease, and death in older adults. Arterioscler Thromb Vasc Biol 36:398\u2013403","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"7384_CR102","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1161\/ATVBAHA.120.315788","volume":"41","author":"A Cornelissen","year":"2021","unstructured":"Cornelissen A, Fuller DT, Fernandez R, Zhao X, Kutys R, Binns-Roemer E, Delsante M, Sakamoto A, Paek KH, Sato Y, Kawakami R, Mori M, Kawai K, Yoshida T, Latt KZ, Miller CL, de Vries PS, Kolodgie FD, Virmani R, Shin MK, Hoek M, Heymann J, Kopp JB, Rosenberg AZ, Davis HR, Guo L, Finn AV (2021) APOL1 genetic variants are associated with increased risk of coronary atherosclerotic plaque rupture in the Black population. Arterioscler Thromb Vasc Biol 41:2201\u20132214","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"7384_CR103","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ekir.2017.08.007","volume":"3","author":"MD Hughson","year":"2018","unstructured":"Hughson MD, Hoy WE, Mott SA, Bertram JF, Winkler CA, Kopp JB (2018) APOL1 risk variants independently associated with early cardiovascular disease death. Kidney Int Rep 3:89\u201398","journal-title":"Kidney Int Rep"},{"key":"7384_CR104","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.ekir.2017.03.008","volume":"2","author":"BI Freedman","year":"2017","unstructured":"Freedman BI, Rocco MV, Bates JT, Chonchol M, Hawfield AT, Lash JP, Papademetriou V, Sedor JR, Servilla K, Kimmel PL, Wall BM, Pajewski NM (2017) APOL1 renal-risk variants do not associate with incident cardiovascular disease or mortality in the Systolic Blood Pressure Intervention Trial. Kidney Int Rep 2:713\u2013720","journal-title":"Kidney Int Rep"},{"key":"7384_CR105","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1161\/ATVBAHA.117.309384","volume":"37","author":"TK Chen","year":"2017","unstructured":"Chen TK, Appel LJ, Grams ME, Tin A, Choi MJ, Lipkowitz MS, Winkler CA, Estrella MM (2017) APOL1 risk variants and cardiovascular disease: results from the AASK (African American Study of Kidney Disease and Hypertension). Arterioscler Thromb Vasc Biol 37:1765\u20131769","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"7384_CR106","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.kint.2017.08.019","volume":"93","author":"OM Guti\u00e9rrez","year":"2018","unstructured":"Guti\u00e9rrez OM, Limou S, Lin F, Peralta CA, Kramer HJ, Carr JJ, Bibbins-Domingo K, Winkler CA, Lewis CE, Kopp JB (2018) APOL1 nephropathy risk variants do not associate with subclinical atherosclerosis or left ventricular mass in middle-aged Black adults. Kidney Int 93:727\u2013732","journal-title":"Kidney Int"},{"key":"7384_CR107","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1681\/ASN.2019030240","volume":"30","author":"ME Grams","year":"2019","unstructured":"Grams ME, Surapaneni A, Ballew SH, Appel LJ, Boerwinkle E, Boulware LE, Chen TK, Coresh J, Cushman M, Divers J, Guti\u00e9rrez OM, Irvin MR, Ix JH, Kopp JB, Kuller LH, Langefeld CD, Lipkowitz MS, Mukamal KJ, Musani SK, Naik RP, Pajewski NM, Peralta CA, Tin A, Wassel CL, Wilson JG, Winkler CA, Young BA, Zakai NA, Freedman BI (2019) APOL1 kidney risk variants and cardiovascular disease: an individual participant data meta-analysis. J Am Soc Nephrol 30:2027\u20132036","journal-title":"J Am Soc Nephrol"},{"key":"7384_CR108","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/s41577-021-00647-3","volume":"21","author":"L Bird","year":"2021","unstructured":"Bird L (2021) APOL1 variants contribute to racial disparity in sepsis. Nat Rev Immunol 21:759","journal-title":"Nat Rev Immunol"},{"key":"7384_CR109","doi-asserted-by":"publisher","DOI":"10.1186\/s12881-020-01048-4","volume":"21","author":"AK Miller","year":"2020","unstructured":"Miller AK, Azhibekov T, O\u2019Toole JF, Sedor JR, Williams SM, Redline RW, Bruggeman LA (2020) Association of preeclampsia with infant APOL1 genotype in African Americans. BMC Med Genet 21:110","journal-title":"BMC Med Genet"},{"key":"7384_CR110","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ajhg.2018.08.002","volume":"103","author":"KJ Reidy","year":"2018","unstructured":"Reidy KJ, Hjorten RC, Simpson CL, Rosenberg AZ, Rosenblum SD, Kovesdy CP, Tylavsky FA, Myrie J, Ruiz BL, Haque S, Mozhui K, Nelson GW, David VA, Yang X, Suzuki M, Jacob J, Reznik SE, Kaskel FJ, Kopp JB, Winkler CA, Davis RL (2018) Fetal-not maternal-APOL1 genotype associated with risk for preeclampsia in those with African ancestry. Am J Hum Genet 103:367\u2013376","journal-title":"Am J Hum Genet"},{"key":"7384_CR111","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1159\/000529850","volume":"120","author":"T Azhibekov","year":"2023","unstructured":"Azhibekov T, Durodoye R, Miller AK, Simpson CL, Davis RL, Williams SM, Bruggeman LA (2023) Fetal high-risk APOL1 genotype increases risk for small for gestational age in term infants affected by preeclampsia. Neonatology 120:532\u2013536","journal-title":"Neonatology"},{"key":"7384_CR112","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1007\/s00467-021-04960-w","volume":"36","author":"A Watanabe","year":"2021","unstructured":"Watanabe A, Guaragna MS, Belangero VMS, Casimiro FMS, Pesquero JB, de Santis FL, Palma LMP, Varela P, de Menezes Neves PDM, Lerario AM, de Souza ML, de Mello MP, de Brito Lutaif ACG, Ferrari CR, Sampson MG, Onuchic LF, Nogueira PCK (2021) APOL1 in an ethnically diverse pediatric population with nephrotic syndrome: implications in focal segmental glomerulosclerosis and other diagnoses. Pediatr Nephrol 36:2327\u20132336","journal-title":"Pediatr Nephrol"},{"key":"7384_CR113","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1016\/j.ekir.2024.09.005","volume":"9","author":"A Watanabe","year":"2024","unstructured":"Watanabe A, Miranda de Menezes Neves PD, Nunes K, Lerario AM, Watanabe EH, Ferreira FM, Avancini Costa Malheiros DM, de Moraes Narcizo A, Guaragna MS, de Almeida Araujo S, Cruz TM, Fontes JS, Santoro Belangero VM, Vaisbich MH, Hildebrandt F, Sampson MG, Onuchic LF (2024) Steroid-resistant nephrotic syndrome is associated with a unique genetic profile in a highly admixed pediatric population. Kidney Int Rep 9:3501\u20133516","journal-title":"Kidney Int Rep"},{"key":"7384_CR114","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41581-023-00742-9","volume":"19","author":"CM Kolvenbach","year":"2023","unstructured":"Kolvenbach CM, Shril S, Hildebrandt F (2023) The genetics and pathogenesis of CAKUT. Nat Rev Nephrol 19:709\u2013720","journal-title":"Nat Rev Nephrol"},{"key":"7384_CR115","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s00467-014-3031-0","volume":"30","author":"EI Anyaegbu","year":"2015","unstructured":"Anyaegbu EI, Shaw AS, Hruska KA, Jain S (2015) Clinical phenotype of APOL1 nephropathy in young relatives of patients with end-stage renal disease. Pediatr Nephrol 30:983\u2013989","journal-title":"Pediatr Nephrol"},{"key":"7384_CR116","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1093\/ndt\/gfy176","volume":"34","author":"O Gribouval","year":"2019","unstructured":"Gribouval O, Boyer O, Knebelmann B, Karras A, Dantal J, Fourrage C, Alibeu O, Hogan J, Dossier C, T\u00eate MJ, Antignac C, Servais A (2019) APOL1 risk genotype in European steroid-resistant nephrotic syndrome and\/or focal segmental glomerulosclerosis patients of different African ancestries. Nephrol Dial Transplant 34:1885\u20131893","journal-title":"Nephrol Dial Transplant"},{"key":"7384_CR117","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.kint.2024.07.026","volume":"106","author":"E Sula Karreci","year":"2024","unstructured":"Sula Karreci E, Jacas S, Donovan O, Pintye D, Wiley N, Zsengeller ZK, Schlondorff J, Alper SL, Friedman DJ, Pollak MR (2024) Differing sensitivities to angiotensin converting enzyme inhibition of kidney disease mediated by APOL1 high-risk variants G1 and G2. Kidney Int 106:1072\u20131085","journal-title":"Kidney Int"},{"key":"7384_CR118","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1056\/NEJMoa2202396","volume":"388","author":"O Egbuna","year":"2023","unstructured":"Egbuna O, Zimmerman B, Manos G, Fortier A, Chirieac MC, Dakin LA, Friedman DJ, Bramham K, Campbell K, Knebelmann B, Barisoni L, Falk RJ, Gipson DS, Lipkowitz MS, Ojo A, Bunnage ME, Pollak MR, Altshuler D, Chertow GM (2023) Inaxaplin for proteinuric kidney disease in persons with two APOL1 variants. N Engl J Med 388:969\u2013979","journal-title":"N Engl J Med"},{"key":"7384_CR119","first-page":"64","volume":"4","author":"O Egbuna","year":"2024","unstructured":"Egbuna O, Audard V, Manos G, Tian S, Hagos F, Chertow GM (2024) Safety and tolerability of the APOL1 inhibitor, inaxaplin, following single- and multiple-ascending doses in healthy adults. Glomerular Dis 4:64\u201373","journal-title":"Glomerular Dis"},{"key":"7384_CR120","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41581-023-00721-0","volume":"19","author":"R Gbadegesin","year":"2023","unstructured":"Gbadegesin R, Lane B (2023) Inaxaplin for the treatment of APOL1-associated kidney disease. Nat Rev Nephrol 19:479\u2013480","journal-title":"Nat Rev Nephrol"},{"key":"7384_CR121","doi-asserted-by":"publisher","unstructured":"Limb S, Assimon V, Leeds JM, Dick R, Yu C, Beattie DT, Bronner S, Octaviani A, Hoek M, Bernstein HS (2024) A phase 1 study in healthy adults of the safety, tolerability, and pharmacokinetics of MZE829, an APOL1 inhibitor, for the treatment of APOL1-mediated kidney disease (AMKD): TH-PO617. J Am Soc Nephrol 35:https:\/\/doi.org\/10.1681\/ASN.2024mr1682v1683twq","DOI":"10.1681\/ASN.2024mr1682v1683twq"},{"key":"7384_CR122","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.126124","volume":"4","author":"M Aghajan","year":"2019","unstructured":"Aghajan M, Booten SL, Althage M, Hart CE, Ericsson A, Maxvall I, Ochaba J, Menschik-Lundin A, Hartleib J, Kuntz S, Gattis D, Ahlstr\u00f6m C, Watt AT, Engelhardt JA, Monia BP, Magnone MC, Guo S (2019) Antisense oligonucleotide treatment ameliorates IFN-\u03b3-induced proteinuria in APOL1-transgenic mice. JCI Insight 4:e126124","journal-title":"JCI Insight"},{"key":"7384_CR123","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1016\/j.ekir.2024.06.033","volume":"9","author":"OA Olabisi","year":"2024","unstructured":"Olabisi OA, Barrett NJ, Lucas A, Smith M, Bethea K, Soldano K, Croall S, Sadeghpour A, Chakraborty H, Wolf M (2024) Design and rationale of the phase 2 Baricitinib study in Apolipoprotein L1-mediated kidney disease (JUSTICE). Kidney Int Rep 9:2677\u20132684","journal-title":"Kidney Int Rep"},{"key":"7384_CR124","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1016\/j.ekir.2023.08.028","volume":"8","author":"G Vasquez-Rios","year":"2023","unstructured":"Vasquez-Rios G, De Cos M, Campbell KN (2023) Novel therapies in APOL1-mediated kidney disease: from molecular pathways to therapeutic options. Kidney Int Rep 8:2226\u20132234","journal-title":"Kidney Int Rep"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-026-07384-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-026-07384-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-026-07384-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:03:06Z","timestamp":1790265786000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-026-07384-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":124,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["7384"],"URL":"https:\/\/doi.org\/10.1007\/s00467-026-07384-6","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.\u00a0","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}